NewEdge Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

NewEdge Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.51K	Sell	207 -172	-45%	-$2.75K	﹤0.01%	3811
2026 Q1	$5.62K	Sell	379 -341	-47%	-$4.98K	﹤0.01%	3557
2025 Q4	$11.5K	Buy	720 +513	+248%	+$7.27K	﹤0.01%	3429
2025 Q3	$2.29K	Hold	207	–	–	﹤0.01%	3751
2025 Q2	$1.75K	Hold	207	–	–	﹤0.01%	3641
2025 Q1	$1.66K	Hold	207	–	–	﹤0.01%	3544
2024 Q4	$1.86K	Sell	207 -801	-79%	-$6.54K	﹤0.01%	3466
2024 Q3	$7.39K	Hold	1,008	–	–	﹤0.01%	3033
2024 Q2	$5.76K	Sell	1,008 -4	-0.4%	-$21	﹤0.01%	3051
2024 Q1	$5.07K	Buy	1,012 +7	+0.7%	+$47	﹤0.01%	3135
2023 Q4	$9.04K	Buy	1,005 +4	+0.4%	+$33	﹤0.01%	2901
2023 Q3	$7.78K	Hold	1,001	–	–	﹤0.01%	2664
2023 Q2	$9.69K	Buy	1,001 +801	+401%	+$8.31K	﹤0.01%	2606
2023 Q1	$2.19K	Hold	200	–	–	﹤0.01%	3009
2022 Q4	$1	Buy	+200	New	+$1.16K	﹤0.01%	3981

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Advisors's AUPH Position: Q2 2026 in Review

NewEdge Advisors reduced its Aurinia Pharmaceuticals (AUPH) stake by 45% in Q2 2026, selling an estimated $2.75K and leaving 207 shares worth $3.51K. The position accounts for ﹤0.01% of the portfolio, ranked #3811.

NewEdge Advisors first reported a position in AUPH in Q4 2022 and has held it in 15 quarters since. The position peaked at $11.5K in Q4 2025. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

NewEdge Advisors held 207 shares of Aurinia Pharmaceuticals worth $3.51K as of Q2 2026.
NewEdge Advisors sold 172 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $2.75K.
Aurinia Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3811 holding.
NewEdge Advisors first reported a position in Aurinia Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
NewEdge Advisors's Aurinia Pharmaceuticals position peaked at $11.5K in Q4 2025.
281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.